- Amazing new angulated screw channel concept and tooling must be experienced to be believed
- New cost-effective NobelProcera® Hybrid is ideal restoration for edentulous patients
- Nobel Biocare extends ‘open access’ to 3Shape® users with NobelProcera® zirconia copings
- Dental laboratories will gain more business opportunities from new integrated treatment workflow
ZURICH, Switzerland, 20-2-2014 — /EuropaWire/ — Nobel Biocare continues its drive to deliver innovation to the dental industry with new NobelProcera implant-based CAD/CAM products and solutions at the 149th Chicago Dental Society “Midwinter Meeting,” February 20–22, and the LMT Magazine “Lab Day Chicago 2014,” February 21–22.
“Our new and superior products and solutions are designed to increase patient acceptance for the clinician and efficiency in the lab,” said Richard Laube, Nobel Biocare CEO. “This means that more patients are treated better resulting in more opportunities and stronger businesses for dental professionals.”
Amazing new angulated screw channel concept and tooling must be experienced to be believed
Clinicians will not have experienced this one-of-a-kind solution before. The innovative combination of the NobelProcera Angulated Screw Channel (ASC) abutment and Nobel Biocare’s unique new Omnigrip tooling solve two typical challenges clinicians often face: buccal screw access holes that limit restorative options in the anterior and difficult access in the posterior region from lack of vertical space.
Available in zirconia for Nobel Biocare implants with conical connection, the abutment can be designed with an angulated screw channel of up to 25 degrees from the axis of the implant. Clinicians using the superior Omnigrip friction-based pick-up function gain peace of mind as the screwdriver easily grips the screw at any angle within the available range. The intense grip keeps the screw in position making it less likely to drop while adjusting the insertion angle and finding the first threads for fixation.
New cost-effective NobelProcera® Hybrid is ideal restoration for edentulous patients
The new NobelProcera Hybrid edentulous restoration brings together the best possible acrylic and teeth support with the time-efficient workflow of a fixed implant bar at an attractive price. This practical titanium restoration saves time and money by relying on a full CAD workflow with powerful design flexibility. Fingers in the anterior and retention elements in the posterior enhance the durability of the restoration. The added strength can save the restorative dentist time by reducing the need for chairside repairs.
The Hybrid is a safe, affordable and understandable treatment choice that is easier for a patient to accept. It is also perfectly suited for the All-on-4® treatment concept which enables the restoration of a fully edentulous jaw on just four implants.
Nobel Biocare extends ‘open access’ to 3Shape® users with NobelProcera®zirconia copings
The classic precision-milled zirconia copings from NobelProcera are now available to 3Shape users via the new ‘open access’ program launched last fall by Nobel Biocare beginning with NobelProcera Abutments. After integrating, 3Shape users can access the extensive global production network of NobelProcera to produce high-quality in-lab designed zirconia copings and industry-leading abutments in zirconia and titanium. Interested 3Shape users should contact their local Nobel Biocare representative for availability.
Dental laboratories will gain more business opportunities from new integrated treatment workflow
The NobelProcera 2G System will soon provide laboratories more opportunities in business-building as part of the upcoming integrated and more efficient treatment workflow by Nobel Biocare. A new data-transfer capability between NobelProcera and NobelClinician in the upcoming workflow will allow labs to offer precise data from solid model scans via the NobelConnect network to clinicians diagnosing and planning implant surgeries with the NobelClinician Software. Providing digitized model surface information, such as soft tissue and the diagnostic tooth set-up, will help better integrate the dental laboratory and the dental technician into the treatment planning process. This early involvement can reduce the likelihood of prosthetic challenges occurring after implant placement.
Further information is available from:
Investors and general media:
Investor and Corporate Relations
+41 43 211 42 30, +41 79 430 81 46
Dental Public Relations
+41 43 211 58 24, +41 79 505 50 99
Nobel Biocare (NOBN, SIX Swiss Exchange) is a world leader in the field of innovative implant-based dental restorations. The company’s portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive®, Brånemark System® and NobelReplace®), a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera®), diagnostics, treatment planning and guided surgery solutions (NobelClinician™ and NobelGuide®) and biomaterials (Creos™). Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials. The company is headquartered in Zurich, Switzerland, currently employs approximately 2,500 employees worldwide and recorded revenue of EUR 566.8 million in 2013. Production takes place at seven sites located in Canada, Israel, Japan, Sweden, and the United States. Products and services are available in over 80 countries through subsidiaries and distributors.
This media release contains forward-looking statements based on beliefs of Nobel Biocare’s management. When used in this media release, words such as “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan” and “project” are intended to identify forward-looking statements. They may involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nobel Biocare as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Nobel Biocare disclaims any intention or obligation to update these forward-looking statements.